Abstract: The present disclosure relates to a use of Genipin-1-?-D-gentiobioside in preparation of a drug, specifically for use in a drug that treats respiratory inflammatory injury caused by coronavirus, respiratory syncytial virus, or Mycoplasma pneumoniae infection. The present disclosure has discovered that Genipin-1-?-D-gentiobioside possesses the characteristics of reducing viral load, lung index, and inflammatory cytokines in lung tissue following coronavirus infection, respiratory syncytial virus infection, or Mycoplasma pneumoniae infection. It also demonstrates a significant protective effect against death caused by coronavirus infection.

Abstract: A novel compound represented by general formula I, a pharmaceutically acceptable salt thereof, a solvate, a stereoisomer including mixtures thereof in all ratios, and a pharmaceutical composition containing the compound are provided. Also provided are preparation method for the compound, and applications of the compound, the pharmaceutically acceptable salt thereof, the solvate, and the stereoisomer including the mixtures in all ratios, and in particular to a use of the compound in the preparation of antiviral drugs.